SCHEMBL2855683

SCHEMBL2855683

Nc1cc(F)c2c(c1)c(-c1ccc3ccccc3c1)nn2C(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 9/20 0.40
RIPK2 O43353 1/20 0.40
PIK3CD O00329 7/20 0.39
PRKDC P78527 7/20 0.39
PIK3CA P42336 6/20 0.39
PIK3CB P42338 6/20 0.39
PIK3CG P48736 6/20 0.39
ABL1 P00519 4/20 0.39
ADORA2A P29274 3/20 0.37
ADORA1 P30542 3/20 0.37
EGFR P00533 1/20 0.34
HCK P08631 1/20 0.34
KDR P35968 1/20 0.34
MTOR P42345 1/20 0.34
EPHB4 P54760 1/20 0.34
CYP1A1 P04798 1/20 0.34
CYP1B1 Q16678 1/20 0.34
PDPK1 O15530 1/20 0.34
DHODH Q02127 1/20 0.33
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2857935 0.85 ADORA2A (0.41) ADORA2AADORA1
SCHEMBL2861573 0.84 SRC (0.40) SRCRIPK2PIK3CDPRKDCPIK3CA
SCHEMBL13198228 0.80 SRC (0.48) SRCRIPK2PIK3CDPRKDCPIK3CA
SCHEMBL2861359 0.80 SRC (0.40) SRCRIPK2PIK3CDPRKDCPIK3CA
SCHEMBL2856284 0.75 SRC (0.35) SRCRIPK2PIK3CDPRKDCPIK3CA
SCHEMBL2865946 0.74 ADORA2A (0.40) ADORA2AADORA1
SCHEMBL2869270 0.73 PIK3CD (0.44) SRCRIPK2PIK3CDPRKDCPIK3CA
SCHEMBL4140232 0.71 SRC (0.42) SRCRIPK2PIK3CDPRKDCPIK3CA
SCHEMBL4139789 0.70 SRC (0.37) SRCRIPK2PIK3CDPRKDCPIK3CA
SCHEMBL4141482 0.70 SRC (0.37) SRCRIPK2PIK3CDPRKDCPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-6982274-B2 1H-indazole compound EISAI CO., LTD. (JP) 2006-01-03 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed
US-20040127538-A1 Novel 1h-indazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 SRC 261/4885RIPK2 382/4885PIK3CD 2115/4885
US-20040127538-A1 Novel 1h-indazole compound MAPK1, MAPK14, MAPK3 SRC 258/4885RIPK2 826/4885PIK3CD 2297/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 SRC 261/4885RIPK2 382/4885PIK3CD 2115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.